BAP1 and cancer: Since BAP1 loss-of-function sensitizes cells to DNA repair defects, the use of PARP inhibitors could be considered, especially in combination with or sequentially to therapies inducing double-strand DNA break, such as platinum-based chemotherapy, as observed in other cancer types [124].